Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
NOTRELOAD AI
FedEx Raises Full-Year Profit Outlook After Strong Q3 Results, Freight Spin-Off On Track
FedEx (FDX) raised its full-year fiscal 2026 adjusted EPS guidance to $19.30–$20.10 and revenue growth forecast to 6.0%-6.5% after strong Q3 results. Adjusted earnings hit $5.25 per share, beating estimates.
Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA
Roche halts emugrobart development, clearing path for Scholar Rock's apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential.
Ecolab Closes In on $5 Billion Deal for KKR's AI Cooling Star CoolIT
Ecolab nears $4.5–5B acquisition of CoolIT Systems from KKR, riding AI-driven demand for advanced data-center liquid cooling—up massively from 2023's $270M valuation.
20% of Global LNG Offline – Iran's Missile Barrage Hits Qatar's Energy Heart
Iran's missile strikes cause extensive damage to Qatar's Ras Laffan LNG hub (20% of world supply). Prices soar, Europe & Asia brace for shortages through 2026.
Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth
Eli Lilly’s retatrutide delivered up to 2.0% A1C reduction and 16.8% weight loss (36.6 lbs) in its first Phase 3 trial for type 2 diabetes. Analysts call it a key growth driver for Lilly with strong results vs Mounjaro.